Full Press Release Details
to Present at the 2017 Annual Conference of the American Association for
NEW YORK--(BUSINESS WIRE)--March 29, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that data on its
gene-edited allogeneic CAR T-cells will be presented at the American
Association for Cancer Research (AACR) Annual Meeting. This includes
both wholly-controlled Cellectis programs and Pfizer/Cellectis
collaboration programs. The meeting will be held from April 1st to April
5th, 2017 in Washington, D.C., USA.
Cellectis presentation:
UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia
Targeting CD22 with CAR T-cells
Agn s Gouble1, C cile Schiffer-Mannioui1,
S verine Thomas1, Anne-Sophie Gautron1,
Laurent Poirot1, Julianne Smith2.
Paris, France; 2Cellectis, New York, NY
Innate Effectors in Immunity to Cancer session - section 30
4, 2017, 8:00 AM - 12:00 PM Eastern Time
Pfizer/Cellectis presentations:
Allogeneic EGFRvIII Chimeric Antigen Receptor T Cells for Treatment
Oi Kwan Wong1, Mathilde Dusseaux2, Jing-Tyan Ma1,
Melinda Au1, Sophie Leduc2, Joyce Chou1,
Jessica M. Yu1, Marjorie Bateman1, Thomas Pertel1,
Kevin C. Lindquist1, Julianne Smith3, Barbra Sasu1,
1Pfizer Inc., South San
Francisco, CA; 2Cellectis, Paris, France; 3Cellectis,
Innate Effectors in Immunity to Cancer session - section 30
4, 2017, 8:00 AM - 12:00 PM Eastern Time
Differential modulation of the PD-1 pathway impacts the anti-tumor
activity of CAR T cells
Regina J. Lin1, Anne-Sophie Gautron2, Laurent
Poirot2, Oi Kwan Wong1, Barbra Sasu1,
Francisco, CA; 2Cellectis, Paris, France; 3Cellectis,
Late-Breaking Research: Immunology session - section 35
4, 2017, 8:00 AM - 12:00 PM Eastern Time
Collaboration with Pfizer
In June 2014, Cellectis and Pfizer began collaborating on a joint
clinical development program for UCAR-T therapies, in the field of
oncology, directed at numerous targets selected by Pfizer and several
targets selected by Cellectis.
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering - based on its flagship TALEN products and
meganucleases as well as its pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
owned by the Cellectis Group
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
VP of Communications
Strategic Communications
Caitlin Kasunich, 212-896-1241
Harnest, 646-385-9008
VP of Corporate Strategy and Finance